Factors affecting treatment responses to interferon-alpha in chronic hepatitis C

被引:91
作者
Pawlotsky, JM
RoudotThoraval, F
Bastie, A
Darthuy, F
Remire, J
Metreau, JM
Zafrani, ES
Duval, J
Dhumeaux, D
机构
[1] UNIV PARIS 12,HOP HENRI MONDOR,DEPT EPIDEMIOL,F-94010 CRETEIL,FRANCE
[2] UNIV PARIS 12,HOP HENRI MONDOR,DEPT GASTROENTEROL & HEPATOL,F-94010 CRETEIL,FRANCE
[3] UNIV PARIS 12,HOP HENRI MONDOR,DEPT PATHOL,F-94010 CRETEIL,FRANCE
关键词
D O I
10.1093/infdis/174.1.1
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Parameters have been studied to predict responses to interferon (IFN) therapy for chronic hepatitis C, but the definition of a response, the times at which responses were assessed, and the pretreatment parameters considered differ markedly from study to study. Thus, 113 patients with chronic hepatitis C were treated 3-6 months with 3 MU of IFN-alpha 2a three times a week and assessed for pretreatment parameters predictive of responses to IFN. In a multivariate analysis, a biochemical response (normal aminotransferase activity) at the end of treatment was significantly associated with tow body weight, normal gamma-glutamyl transpeptidase activity, and a pretreatment hepatitis C virus (HCV) genotype other than 1. Six months after the end of treatment, a low virus burden and a lack of anti-HCV IgM core antibodies were independently associated with sustained virologic response (i.e., normal aminotransferase activity and HCV RNA negativity). Therefore, these pretreatment parameters should be taken into account when individual treatment protocols are designed.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 48 条
[1]   DETECTION OF ANTIBODY TO HEPATITIS-C VIRUS IN PROSPECTIVELY FOLLOWED TRANSFUSION RECIPIENTS WITH ACUTE AND CHRONIC NON-A-HEPATITIS, NON-B-HEPATITIS [J].
ALTER, HJ ;
PURCELL, RH ;
SHIH, JW ;
MELPOLDER, JC ;
HOUGHTON, M ;
CHOO, QL ;
KUO, G .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (22) :1494-1500
[2]  
BOUCHER E, 1995, HEPATOLOGY, V21, P322, DOI 10.1016/0270-9139(95)90087-X
[3]  
Boyer N., 1995, Hepatology, V22, p291A, DOI 10.1016/0270-9139(95)94887-2
[4]   PILOT-STUDY OF COMBINATION THERAPY WITH RIBAVIRIN PLUS INTERFERON-ALFA FOR INTERFERON ALFA-RESISTANT CHRONIC HEPATITIS-C [J].
BRILLANTI, S ;
GARSON, J ;
FOLI, M ;
WHITBY, K ;
DEAVILLE, R ;
MASCI, C ;
MIGLIOLI, M ;
BARBARA, L .
GASTROENTEROLOGY, 1994, 107 (03) :812-817
[5]   RANDOMIZED TRIAL OF LYMPHOBLASTOID ALPHA-INTERFERON IN CHRONIC HEPATITIS-C - EFFECTS ON INFLAMMATION, FIBROGENESIS AND VIREMIA [J].
CAMPS, J ;
CASTILLA, A ;
RUIZ, J ;
CIVEIRA, MP ;
PRIETO, J .
JOURNAL OF HEPATOLOGY, 1993, 17 (03) :390-396
[6]   ISOLATION OF A CDNA CLONE DERIVED FROM A BLOOD-BORNE NON-A, NON-B VIRAL-HEPATITIS GENOME [J].
CHOO, QL ;
KUO, G ;
WEINER, AJ ;
OVERBY, LR ;
BRADLEY, DW ;
HOUGHTON, M .
SCIENCE, 1989, 244 (4902) :359-362
[7]  
CIMINO L, 1991, ITAL J GASTROENTEROL, V23, P399
[8]   PREDICTION OF RESPONSE TO INTERFERON TREATMENT OF CHRONIC HEPATITIS-C [J].
DAVIS, GL .
JOURNAL OF HEPATOLOGY, 1994, 21 (01) :1-3
[9]   Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched-DNA technology [J].
Detmer, J ;
Lagier, R ;
Flynn, J ;
Zayati, C ;
Kolberg, J ;
Collins, M ;
Urdea, M ;
SanchezPescador, R .
JOURNAL OF CLINICAL MICROBIOLOGY, 1996, 34 (04) :901-907
[10]   RECOMBINANT INTERFERON-ALFA THERAPY FOR CHRONIC HEPATITIS-C - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
DIBISCEGLIE, AM ;
MARTIN, P ;
KASSIANIDES, C ;
LISKERMELMAN, M ;
MURRAY, L ;
WAGGONER, J ;
GOODMAN, Z ;
BANKS, SM ;
HOOFNAGLE, JH .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (22) :1506-1510